Business Context and Reporting Period
This Form 8-K Current Report was filed by Arvinas, Inc. on December 5, 2023. The filing discloses interim clinical trial data for vepdegestrant (ARV-471), an investigational orally bioavailable PROTAC ER degrader co-developed with Pfizer, Inc. The data pertains to a Phase 1b clinical trial evaluating vepdegestrant in combination with palbociclib (IBRANCE) for patients with locally advanced or metastatic ER+/HER2- breast cancer. The results were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical trial updates and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Clinical Data
The primary material update is the release of interim data from the ARV-471-mBC-101 Phase 1b trial involving 46 heavily pre-treated patients (median of four prior therapies). Key clinical outcomes include:
- Clinical Benefit Rate (CBR): 63% overall (29 of 46 patients). At the recommended Phase 3 dose (RP3D) of 200 mg, CBR was 67%.
- ESR1 Mutation Status: CBR was 72% in patients with mutant ESR1 and 53% in patients with wild-type ESR1.
- Objective Response Rate (ORR): 42% in evaluable patients (13 of 31). At the RP3D of 200 mg, ORR was 53%.
- Progression-Free Survival (PFS): Median PFS was 11.1 months overall. Median duration of response was 10.2 months.
- Safety Profile: The primary toxicity was neutropenia. Grade 3/4 neutropenia occurred in 89% of all patients. Grade 4 neutropenia occurred in 38% of patients treated at the RP3D. No cases of febrile neutropenia were reported.
- Pharmacokinetics: An increase in palbociclib exposure (46% - 58%) was observed compared to historical data.
Guidance, Outlook, and Risks
Future Development Plans: Arvinas and Pfizer plan to initiate new Phase 3 trials pending regulatory feedback expected in the second half of 2024. These include a second-line trial of vepdegestrant plus palbociclib and a first-line trial of vepdegestrant plus Pfizer's novel CDK4 inhibitor (PF-07220060). A readout for the VERITAC-2 Phase 3 monotherapy trial is expected in the second half of 2024.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the ability to successfully conduct clinical development, obtain marketing approval, and the sufficiency of cash resources to fund operations. The company notes that actual results may differ materially from expectations due to collaboration performance and regulatory outcomes.
Investor Verification Checklist
- Verify the specific eligibility criteria and patient demographics for the Phase 1b trial to assess the generalizability of the 63% CBR.
- Confirm the timeline for regulatory feedback on the proposed new Phase 3 trials, currently expected in the second half of 2024.
- Monitor the safety data regarding Grade 4 neutropenia (38% at RP3D) and its impact on dose reductions or discontinuations in larger Phase 3 cohorts.
- Review the company's cash runway and capital requirements in subsequent filings (e.g., 10-K or 10-Q) as this 8-K does not provide liquidity data.
- Track the upcoming VERITAC-2 Phase 3 monotherapy readout scheduled for the second half of 2024.